×
About 122 results

ALLMedicine™ N-terminal Telopeptide Center

Research & Reviews  61 results

Serum N-terminal telopeptide of type I collagen as a biomarker for predicting bone dens...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078791
PloS One; Ishida N, Higuchi T et. al.

Apr 27th, 2021 - The serum N-terminal telopeptide of type I collagen (NTx) is significantly higher in patients with Crohn disease (CD) than in healthy individuals and patients with ulcerative colitis. This study aimed to investigate whether an elevated serum NTx l...

A phase 1 pooled PK/PD analysis of bone resorption biomarkers for odanacatib, a Catheps...
https://doi.org/10.1007/s10928-020-09699-9
Journal of Pharmacokinetics and Pharmacodynamics; Zajic S, Stoch SA et. al.

Jul 10th, 2020 - To develop a framework for evaluating the resorption effects of Cathepsin K (CatK) inhibitors and to inform dose regimen selection, a pharmacokinetic/pharmacodynamic (PK/PD) model for odanacatib (ODN) was developed based upon data from Phase 1 stu...

N-Terminal Telopeptide 
https://emedicine.medscape.com/article/2093977-overview

Feb 17th, 2020 - Reference Range The biomarker N-terminal telopeptide (NTX), as detected in urine, is reported in nmol of bone collagen equivalents (BCE)/mmol creatinine. Therefore, detectable levels of creatinine in urine are needed to report normalized levels of...

N-Terminal Telopeptide 
https://emedicine.medscape.com/article/2093977-print

Feb 17th, 2020 - The biomarker N-terminal telopeptide (NTX), as detected in urine, is reported in nmol of bone collagen equivalents (BCE)/mmol creatinine. Therefore, detectable levels of creatinine in urine are needed to report normalized levels of NTX.[1] The ref...

Effects of telmisartan and losartan treatments on bone turnover markers in patients wit...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647217
Journal of the Renin-angiotensin-aldosterone System : JRAAS; Aydoğan BI, Erarslan E et. al.

Jul 22nd, 2019 - Telmisartan is an angiotensin-II receptor type-1 blocker and a partial agonist for peroxisome proliferator-activated receptor-γ. The aim of this study was to determine the potential effects of telmisartan on bone metabolism and turnover markers. F...

see more →

Clinicaltrials.gov  61 results

Serum N-terminal telopeptide of type I collagen as a biomarker for predicting bone dens...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078791
PloS One; Ishida N, Higuchi T et. al.

Apr 27th, 2021 - The serum N-terminal telopeptide of type I collagen (NTx) is significantly higher in patients with Crohn disease (CD) than in healthy individuals and patients with ulcerative colitis. This study aimed to investigate whether an elevated serum NTx l...

A phase 1 pooled PK/PD analysis of bone resorption biomarkers for odanacatib, a Catheps...
https://doi.org/10.1007/s10928-020-09699-9
Journal of Pharmacokinetics and Pharmacodynamics; Zajic S, Stoch SA et. al.

Jul 10th, 2020 - To develop a framework for evaluating the resorption effects of Cathepsin K (CatK) inhibitors and to inform dose regimen selection, a pharmacokinetic/pharmacodynamic (PK/PD) model for odanacatib (ODN) was developed based upon data from Phase 1 stu...

N-Terminal Telopeptide 
https://emedicine.medscape.com/article/2093977-overview

Feb 17th, 2020 - Reference Range The biomarker N-terminal telopeptide (NTX), as detected in urine, is reported in nmol of bone collagen equivalents (BCE)/mmol creatinine. Therefore, detectable levels of creatinine in urine are needed to report normalized levels of...

N-Terminal Telopeptide 
https://emedicine.medscape.com/article/2093977-print

Feb 17th, 2020 - The biomarker N-terminal telopeptide (NTX), as detected in urine, is reported in nmol of bone collagen equivalents (BCE)/mmol creatinine. Therefore, detectable levels of creatinine in urine are needed to report normalized levels of NTX.[1] The ref...

Effects of telmisartan and losartan treatments on bone turnover markers in patients wit...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647217
Journal of the Renin-angiotensin-aldosterone System : JRAAS; Aydoğan BI, Erarslan E et. al.

Jul 22nd, 2019 - Telmisartan is an angiotensin-II receptor type-1 blocker and a partial agonist for peroxisome proliferator-activated receptor-γ. The aim of this study was to determine the potential effects of telmisartan on bone metabolism and turnover markers. F...

see more →